Giant Cell Arteritis & Ischemic Optic Neuropathy

Ischemic optic neuropathy (ION) is one of the leading causes of severe visual acuity loss in people over 50, anatomically divided into anterior (AION, affecting the optic nerve head, visible as disc edema) and posterior (PION, affecting the retrobulbar nerve, normal-appearing disc acutely) forms.¹ The single most important diagnostic branch point is arteritic versus non-arteritic disease: arteritic AION, caused by giant cell arteritis (GCA), requires emergent recognition and treatment to prevent blindness, stroke, and death, while non-arteritic AION has a different, much broader set of risk factors and no proven acute treatment.¹ PION can also be arteritic or non-arteritic, and is a recognized perioperative complication, particularly after prolonged prone spine surgery with significant blood loss.¹

GCA is the most common systemic vasculitis of the elderly, though incidence and presentation vary meaningfully by population — highest among Northern Europeans, lowest among East Asians.⁴ Non-arteritic AION, once GCA is excluded, is a distinct and much more common category, typically involving a local anatomic predisposition (a small, crowded "disc at risk" or optic disc drusen) combined with a precipitating factor (severe hypotension, general anesthesia, dialysis) in the setting of underlying vascular disease (obstructive sleep apnea, hypertension, diabetes).¹ Arteritic AION results from granulomatous inflammation of the posterior ciliary arteries causing thrombotic occlusion and infarction of the nerve; as a systemic vasculitis, GCA also produces amaurosis fugax, diplopia, jaw claudication, scalp tenderness, and stroke risk.³ Non-arteritic AION instead reflects transient hypoperfusion in an anatomically crowded optic nerve head — a mechanistically distinct process from vasculitis despite similar acute appearance.¹

Patients with AION of either type report sudden, painless monocular vision loss, often noticed on waking. Arteritic AION is frequently, though not always, accompanied by new headache, scalp tenderness, jaw claudication, and constitutional symptoms. Prodromal amaurosis fugax, blurred vision episodes, or diplopia may herald impending permanent visual loss, and recognizing these is critical to preventing blindness.³

Key differentials: optic neuritis (younger, painful, different time course), compressive optic neuropathy, papilledema (bilateral, from raised ICP), central retinal artery occlusion (retinal rather than optic-nerve-head circulation), and diabetic papillopathy (more favorable prognosis).

AION shows a pale, edematous optic disc (both arteritic and non-arteritic), sometimes with cotton-wool spots or flame hemorrhages, a pronounced relative afferent pupillary defect, and classically an altitudinal visual field defect. Arteritic disease may show scalp/temporal artery tenderness or a thickened, nonpulsatile temporal artery. Elevated ESR/CRP occur in most but not all GCA cases; a notable minority of GCA-related visual loss cases occur with only modestly elevated ESR alongside a higher hemoglobin level, one of several predictors of permanent visual loss.³

Suspected arteritic AION/GCA is a true emergency: high-dose corticosteroid treatment should start immediately on clinical suspicion, without waiting for biopsy confirmation, because untreated GCA is associated with fellow-eye visual loss within days in up to half of affected individuals.³ Treatment typically begins with high-dose IV methylprednisolone, then oral prednisone (~1 mg/kg/day), with adjunctive aspirin considered given retrospective evidence of protection against stroke and further visual loss.³ Temporal artery biopsy remains the standard confirmatory test but is often delayed several days; vascular (temporal artery) ultrasound has emerged as a rapid, reliable point-of-care alternative in experienced hands, reducing unnecessary prolonged steroid exposure in patients who ultimately don't have GCA.² Duration of treatment is not rigidly standardized given a significant risk of late recurrence during tapering; glucocorticoids remain the backbone of therapy, with steroid-sparing/biologic agents (including IL-6 blockade) reserved for steroid-refractory or relapsing disease.⁴ Non-arteritic AION has no proven acute treatment; management centers on addressing underlying vascular risk factors to reduce contralateral recurrence risk, which can occur even years later.¹

• Any patient over 50 with acute painless vision loss and a pale, edematous disc should be evaluated for GCA symptoms before assuming non-arteritic disease
• Treat suspected arteritic AION with high-dose corticosteroids immediately on clinical suspicion, without waiting for biopsy³
• Temporal artery ultrasound is a validated, rapid alternative or adjunct to biopsy that can avoid unnecessary prolonged steroid exposure²
• A near-normal ESR does not reliably exclude GCA³
• Common pitfall: delaying corticosteroid treatment pending temporal artery biopsy results, risking irreversible fellow-eye vision loss
• Common pitfall: assuming a normal ESR excludes GCA³
• Common pitfall: failing to distinguish anterior from posterior ischemic optic neuropathy, since PION presents with a normal-appearing disc acutely¹